Suchen
Matinas BioPharma Holdings Inc
MTNBZur Watchlist hinzufügen
0.665USD
+0.001+0.09%
Handelsschluss 06/30, 16:00（ET）Kurse um 15 Minuten verzögert
3.92MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Matinas BioPharma Holdings Inc Unternehmen
Matinas BioPharma Holdings, Inc. is a biopharmaceutical company. The Company is focused on delivering therapies using its lipid nanocrystal (LNC) platform delivery technology. Its lead product candidate is MAT2203 (oral amphotericin B), a highly potent antifungal drug which, by virtue of LNC delivery, has been made oral, safe, and well-tolerated for prolonged administration in patients with life-threatening invasive fungal infections. MAT2203 has completed a Phase II encochleated oral amphotericin for cryptococcal meningitis trial (EnACT) study in HIV patients suffering from cryptococcal meningitis, meeting its primary endpoint and achieving robust survival. MAT2203 is now positioned for a single, Phase III registration trial (the ORALTO trial) in support of a New Drug Application (NDA) for the treatment of invasive aspergillosis in patients with limited treatment options.
Matinas BioPharma Holdings Inc Informationen
BörsenkürzelMTNB
Name des UnternehmensMatinas BioPharma Holdings Inc
IPO-datumJun 03, 2014
CEOJabbour (Jerome D)
Anzahl der mitarbeiter3
WertpapierartOrdinary Share
GeschäftsjahresendeJun 03
AddresseSuite 302
StadtBEDMINSTER
BörseNASDAQ OMX – NASDAQ Basic Amex
LandUnited States of America
Postleitzahl07921
Telefon19084431860
Websitehttps://www.matinasbiopharma.com/
BörsenkürzelMTNB
IPO-datumJun 03, 2014
CEOJabbour (Jerome D)
Führungskräfte von Matinas BioPharma Holdings Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jerome D. Jabbour, J.D.
Mr. Jerome D. Jabbour, J.D.
Chairman of the Board, President, Chief Executive Officer, Director
Chairman of the Board, President, Chief Executive Officer, Director
9.21K
--
Mr. Keith A. Kucinski, CPA
Mr. Keith A. Kucinski, CPA
Chief Financial Officer
Chief Financial Officer
1.89K
--
Ms. Evelyn D'An
Ms. Evelyn D'An
Independent Director
Independent Director
--
--
Dr. Robin L. Smith
Dr. Robin L. Smith
Independent Director
Independent Director
--
--
Mr. Keith E. Murphy
Mr. Keith E. Murphy
Independent Director
Independent Director
--
--
Mr. Edward Neugeboren
Mr. Edward Neugeboren
Independent Director
Independent Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Matinas BioPharma Holdings Inc?
Die fünf größten Anteilseigner von Matinas BioPharma Holdings Inc sind: Mr. Jerome D. Jabbour, J.D.
Wie viele Institutionen halten Anteile an Matinas BioPharma Holdings Inc (MTNB)?
Mit Stand vom 2026Q1 halten 81 Institutionen Anteile an Matinas BioPharma Holdings Inc, mit einem Gesamtmarktwert von etwa 511.24K, was 7.98% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -956971.00 gestiegen.
